Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 499-503

  Demolis, J L ^a   Charransol, A ^a   Funck Brentano, C ^a   Jaillon, P ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

QT interval; repolarization; reverse rate dependence; sparfloxacin

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; EXERCISE; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; R WAVE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029931222     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03394.x     Document Type: Article

References (22)

1. Nakamura S, Minami, Nakata K, et al. In vivo and in vitro antibacterial activity of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother 1989; 33: 1167-1173.
2. Kojima T, Inoue M, Mitsuhashu S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother 1989; 33: 1980-1988.
3. Chin NY, Gu JW, Yu KW, Zhang YX, Neu HC. In vitro activity of sparfloxacin. Antimicrob Agents Chemother 1991; 35: 567-571.
4. Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother 1991; 35: 955-960.
5. Azoulay-Dupuis E, Vallée E, Veber B, Bedos JP, Bauchet J, Pocidalo JJ. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob. Agents Chemother 1992; 36: 2698-2703.
6. Jaillon P, Morganroth J, Brumpt I, Talbot G. for the Sparfloxacin Safety Board. Sparfloxacin: An overview of an independent Safety Board assessment of electrocardiographic and cardiovascular safety data. J Am Coll Cardiol 1996; (in press).
7. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989; 63: 867-869.
8. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113: 1470-1482.
9. Benedict CR: The QT interval and drug-associated torsades de pointes. Drug Invest 1993; 5: 69-79.
10. Hondeghem LM, Snyder S. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686-690.
11. Funck-Brentano C: Rate dependence of class III actions in the heart. Fundam Clin Pharmacol 1993; 7: 51-59.
12. Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200. 400, 600, and 800 mg. J Clin Pharmacol 1994; 34: 1071-1076.
13. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952; 6: 378-388.
14. Sarma JSM, Sarma JR, Bilitch M, Katz D, Song SL. An exponential formula for heart dependence of QT interval during exercise and cardiac pacing in humans: re-evaluation of Bazett's formula. Am J Cardiol 1984; 54: 103-108.
15. Lecocq B, Lecocq V, Jaillon P. Physiologic relation between cardiac cycle and QT duration in healthy volunteers. Am J Cardiol 1989; 63: 481-486.
16. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM. Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991; 83: 536-545.
17. McComb JM, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984; 54: 922-923.
18. Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993; 12: 688-691.
19. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent 'Torsades de pointes' during erythromycin lactobionate infusion. Am J Cardiol 1986; 58: 666.
20. Brandriss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis 1994; 18: 995-998.
21. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 91: 3010-3016.
22. Funck-Brentano C, Demolis JL, Ropers J, Ghadanfar M, Jaillon P. Influence of dofetilide on QT interval duration and QT interval dispersion at various heart rates in humans. Circulation 1995; 8 (Suppl I): I-276.